{"denoms":[{"counts":[{"groupId":"BG000","value":"63"}],"units":"Participants"}],"groups":[{"description":"Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR. Eligible patients who received any treatment were included in baseline measures.","id":"BG000","title":"Gemcitabine and Paclitaxel"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"40.7","upperLimit":"82.9","value":"63.1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"56"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Lip/Oral Cavity"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Nasopharynx"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Oropharynx"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Salivary glands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Hypopharynx"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Larynx"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Paranasal Sinuses"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Other/Unknown"}],"paramType":"NUMBER","title":"Primary Site","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Newly Diagnosed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Persistent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"}]}],"title":"Recurrent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Disease Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"39"}]}],"title":"1"}],"description":"Performance status is graded according to the Zubrod Performance Status Scale. Patients with a performance status of 0 are fully active, able to carry on all pre-disease performance without restriction. Patients with a performance status of 1 are restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.","paramType":"NUMBER","title":"Performance Status","unitOfMeasure":"participants"}]}